ZOETIS INC. (ZTS) is a publicly traded Healthcare sector company. As of November 17, 2026, ZTS trades at $83.78 with a market cap of $34.06B and a P/E ratio of 12.06. ZTS moved -0.73% today. Year to date, ZTS is -32.97%; over the trailing twelve months it is -30.15%. Its 52-week range spans $68.77 to $172.23. Analyst consensus is buy with an average price target of $87.00. Rallies surfaces ZTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zoetis receives USDA licensure for Cytopoint Plus and plans 12 pet medicines for Japan: Zoetis received USDA licensure for Cytopoint Plus, which provides 75 days of allergic itch relief per injection. Zoetis reportedly intends to bring 12 potential blockbuster pet medicines in its pipeline to Japan.
| Metric | Value |
|---|---|
| Price | $83.78 |
| Market Cap | $34.06B |
| P/E Ratio | 12.06 |
| EPS | $6.08 |
| Dividend Yield | 0.53% |
| 52-Week High | $172.23 |
| 52-Week Low | $68.77 |
| Volume | 1.46K |
| Avg Volume | 0 |
| Revenue (TTM) | $9.52B |
| Net Income | $2.62B |
| Gross Margin | 71.53% |
11 analysts cover ZTS: 0 strong buy, 3 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $87.00.